The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Gastrinoma

  • Selective intra-arterial methylene blue injection can enhance intraoperative detection of small gastrinomas and may improve the rate of curative resection in the Zollinger-Ellison syndrome [1].
  • It is postulated that the abnormal stimulation of antral gastrin release may on occasions give rise to antral G-cell hyperplasia, and that the abnormal secretion of gastrin into gastric juice may on occasions give rise to gastrinomas [2].
  • The dramatic clinical improvement after subsiding of the intercurrent illness was obviously linked to pronounced failure of the parietal cell mass for acid secretion and not to infarction of the gastrinoma because gastrin secretion by the tumor was unchanged [3].
  • One copy of the MEN1 gene was found to be deleted in 25 of 27 (93%) sporadic gastrinomas and in 6 of 12 (50%) sporadic insulinomas [4].
  • Analysis of CD44 splice variants showed that in all five gastrinomas there was overproduction of alternatively spliced larger molecular variants as compared with other types of endocrine pancreatic tumors and carcinoid tumors [5].

High impact information on Gastrinoma

  • Brief report: a duodenal gastrinoma in a patient with diarrhea and normal serum gastrin concentrations [6].
  • It is likely that these lesions precede the development of MEN1-associated duodenal gastrinomas [7].
  • RESULTS: We confirmed the molecular nature of the secretin receptor in the gastrinomas with a positive provocative test result and identified a novel mechanism for a false-negative result [8].
  • The exact identification of this gastrinoma in an extra-abdominal site was facilitated by the use of [111In-DTPA-DPhe1]octreotide scanning for somatostatin receptors, which these tumors characteristically possess in high numbers [9].
  • If a primary gastrinoma cannot be identified by SRS or STIR-MRI, endoscopic ultrasonography should be undertaken because duodenal gastrinomas are often minute and multicentric [10].

Chemical compound and disease context of Gastrinoma


Biological context of Gastrinoma

  • Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas [4].
  • In the present study HER-2/neu gene amplification and expression was determined in 43 gastrinomas from different patients [14].
  • A heterozygous point mutation in the p53 gene (codon 273) was found in a single sample; none of the gastrinomas contained a mutation of the ras genes [15].
  • Furthermore, because it is independent of disease stage it is probably an early event in the pathogenesis and because it is independent of the primary gastrinoma location, which is now thought to have different origins, methylation of the p16INK4a gene is probably a central process in the molecular pathogenesis of these tumors [16].
  • DNA was extracted from frozen gastrinomas from 51 patients and screened by dideoxyfinger-printing (ddF) for abnormalities in the 9 coding exons and adjacent splice junctions of the MEN1 gene [17].

Anatomical context of Gastrinoma


Gene context of Gastrinoma


Analytical, diagnostic and therapeutic context of Gastrinoma


  1. Selective intra-arterial methylene blue injection: a novel method of localizing gastrinoma. Ko, T.C., Flisak, M., Prinz, R.A. Gastroenterology (1992) [Pubmed]
  2. Is peptic ulceration a hormonal disease? Fiddian-Green, R.G. Lancet (1977) [Pubmed]
  3. Clinical recovery owing to target parietal cell failure in a patient with Zollinger-Ellison syndrome. Wiersinga, W.M., Tytgat, G.N. Gastroenterology (1977) [Pubmed]
  4. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Zhuang, Z., Vortmeyer, A.O., Pack, S., Huang, S., Pham, T.A., Wang, C., Park, W.S., Agarwal, S.K., Debelenko, L.V., Kester, M., Guru, S.C., Manickam, P., Olufemi, S.E., Yu, F., Heppner, C., Crabtree, J.S., Skarulis, M.C., Venzon, D.J., Emmert-Buck, M.R., Spiegel, A.M., Chandrasekharappa, S.C., Collins, F.S., Burns, A.L., Marx, S.J., Lubensky, I.A. Cancer Res. (1997) [Pubmed]
  5. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Chaudhry, A., Gobl, A., Eriksson, B., Skogseid, B., Oberg, K. Cancer Res. (1994) [Pubmed]
  6. Brief report: a duodenal gastrinoma in a patient with diarrhea and normal serum gastrin concentrations. Zimmer, T., Stölzel, U., Bäder, M., Fett, U., Foss, H.D., Riecken, E.O., Rehfeld, J.F., Wiedenmann, B. N. Engl. J. Med. (1995) [Pubmed]
  7. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Anlauf, M., Perren, A., Meyer, C.L., Schmid, S., Saremaslani, P., Kruse, M.L., Weihe, E., Komminoth, P., Heitz, P.U., Klöppel, G. Gastroenterology (2005) [Pubmed]
  8. Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Ding, W.Q., Kuntz, S., Böhmig, M., Wiedenmann, B., Miller, L.J. Gastroenterology (2002) [Pubmed]
  9. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome. Gibril, F., Curtis, L.T., Termanini, B., Fritsch, M.K., Lubensky, I.A., Doppman, J.L., Jensen, R.T. Gastroenterology (1997) [Pubmed]
  10. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Modlin, I.M., Tang, L.H. Gastroenterology (1997) [Pubmed]
  11. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Cadiot, G., Lebtahi, R., Sarda, L., Bonnaud, G., Marmuse, J.P., Vissuzaine, C., Ruszniewski, P., Le Guludec, D., Mignon, M. Gastroenterology (1996) [Pubmed]
  12. Mechanism for increase of gastrin release by secretin in Zollinger-Ellison syndrome. Chiba, T., Yamatani, T., Yamaguchi, A., Morishita, T., Nakamura, A., Kadowaki, S., Fujita, T. Gastroenterology (1989) [Pubmed]
  13. Progastrin and its glycine-extended posttranslational processing intermediates in human gastrointestinal tissues. Del Valle, J., Sugano, K., Yamada, T. Gastroenterology (1987) [Pubmed]
  14. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Goebel, S.U., Iwamoto, M., Raffeld, M., Gibril, F., Hou, W., Serrano, J., Jensen, R.T. Cancer Res. (2002) [Pubmed]
  15. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Evers, B.M., Rady, P.L., Sandoval, K., Arany, I., Tyring, S.K., Sanchez, R.L., Nealon, W.H., Townsend, C.M., Thompson, J.C. Ann. Surg. (1994) [Pubmed]
  16. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. Serrano, J., Goebel, S.U., Peghini, P.L., Lubensky, I.A., Gibril, F., Jensen, R.T. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  17. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. Goebel, S.U., Heppner, C., Burns, A.L., Marx, S.J., Spiegel, A.M., Zhuang, Z., Lubensky, I.A., Gibril, F., Jensen, R.T., Serrano, J. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  18. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Vinik, A.I., Tsai, S.T., Moattari, A.R., Cheung, P., Eckhauser, F.E., Cho, K. Am. J. Med. (1986) [Pubmed]
  19. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Imamura, M., Takahashi, K., Adachi, H., Minematsu, S., Shimada, Y., Naito, M., Suzuki, T., Tobe, T., Azuma, T. Ann. Surg. (1987) [Pubmed]
  20. Expression of peptide receptors in human endocrine tumours of the pancreas. Tang, C., Biemond, I., Lamers, C.B. Gut (1997) [Pubmed]
  21. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Peghini, P.L., Iwamoto, M., Raffeld, M., Chen, Y.J., Goebel, S.U., Serrano, J., Jensen, R.T. Clin. Cancer Res. (2002) [Pubmed]
  22. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Hofland, L.J., van Koetsveld, P.M., Waaijers, M., Zuyderwijk, J., Lamberts, S.W. Endocrinology (1994) [Pubmed]
  23. Bilateral pituitary adenomas occurring with multiple endocrine neoplasia type one. Sahdev, A., Jäger, R. AJNR. American journal of neuroradiology. (2000) [Pubmed]
  24. Resection of gastrinoma in the Zollinger-Ellison syndrome. Barreras, R.F., Mack, E., Goodfriend, T., Damm, M. Gastroenterology (1982) [Pubmed]
  25. Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Fishbeyn, V.A., Norton, J.A., Benya, R.V., Pisegna, J.R., Venzon, D.J., Metz, D.C., Jensen, R.T. Ann. Intern. Med. (1993) [Pubmed]
  26. The early diagnosis of gastrinoma. Modlin, I.M., Jaffe, B.M., Sank, A., Albert, D. Ann. Surg. (1982) [Pubmed]
  27. Observations on the postoperative tumor growth behavior of certain islet cell tumors. Zollinger, R.M., Martin, E.W., Carey, L.C., Sparks, J., Minton, J.P. Ann. Surg. (1976) [Pubmed]
WikiGenes - Universities